Search research articles
Contact Us
Filters
Showing results (61-70 of 121) with videos related to
Page
of 13
Sort By:
Cancer
|
June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
Daniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
European Urology
|
April 19, 2021
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
Thomas E Hutson, M Dror Michaelson, Timothy M Kuzel, et al.
Clinical Genitourinary Cancer
|
February 9, 2013
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib
Brian I Rini, Thibault de La Motte Rouge, Andrea L Harzstark, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 24, 2017
A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524)
M Dror Michaelson, Chen Hu, Huong T Pham, et al.
The Lancet. Oncology
|
April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
Cancer Chemotherapy and Pharmacology
|
November 14, 2013
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
Charles S Harmon, Samuel E DePrimo, Robert A Figlin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Lancet. Oncology
|
October 26, 2007
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Olivier Rixe, Ronald M Bukowski, M Dror Michaelson, et al.
Nature Medicine
|
August 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Cancer
|
November 25, 2010
Sunitinib rechallenge in metastatic renal cell carcinoma patients
Ivan N Zama, Thomas E Hutson, Paul Elson, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 121) with videos related to
Sort By:
Page
of 13
Cancer
|
June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
Daniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
European Urology
|
April 19, 2021
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
Thomas E Hutson, M Dror Michaelson, Timothy M Kuzel, et al.
Clinical Genitourinary Cancer
|
February 9, 2013
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib
Brian I Rini, Thibault de La Motte Rouge, Andrea L Harzstark, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 24, 2017
A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524)
M Dror Michaelson, Chen Hu, Huong T Pham, et al.
The Lancet. Oncology
|
April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
Robert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
Cancer Chemotherapy and Pharmacology
|
November 14, 2013
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
Charles S Harmon, Samuel E DePrimo, Robert A Figlin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Lancet. Oncology
|
October 26, 2007
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Olivier Rixe, Ronald M Bukowski, M Dror Michaelson, et al.
Nature Medicine
|
August 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Cancer
|
November 25, 2010
Sunitinib rechallenge in metastatic renal cell carcinoma patients
Ivan N Zama, Thomas E Hutson, Paul Elson, et al.
Page
of 13